5002572025-04-012025-06-305002572025-06-305002572025-04-012025-06-30in-capmkt:OtherExpenses1Member5002572025-04-012025-06-30in-capmkt:OtherExpenses2Member5002572025-04-012025-06-30in-capmkt:ReportableSegments1Member5002572025-04-012025-06-30in-capmkt:ReportableSegments2Member5002572025-04-012025-06-30in-capmkt:ReportableSegments8Member5002572025-04-012025-06-30in-capmkt:ReportableSegments9Member5002572025-04-012025-06-30in-capmkt:ReportableSegments1Member5002572025-04-012025-06-30in-capmkt:ReportableSegments2Member5002572025-04-012025-06-30in-capmkt:ReportableSegments8Member5002572025-04-012025-06-30in-capmkt:ReportableSegments9Member5002572025-04-012025-06-30in-capmkt:ReportableSegments1Member5002572025-06-30in-capmkt:ReportableSegments1Member5002572025-04-012025-06-30in-capmkt:ReportableSegments2Member5002572025-06-30in-capmkt:ReportableSegments2Member5002572025-04-012025-06-30in-capmkt:ReportableSegments8Member5002572025-06-30in-capmkt:ReportableSegments8Member5002572025-04-012025-06-30in-capmkt:ReportableSegments9Member5002572025-06-30in-capmkt:ReportableSegments9Member5002572025-04-012025-06-30in-capmkt:ReportableSegments1Member5002572025-06-30in-capmkt:ReportableSegments1Member5002572025-04-012025-06-30in-capmkt:ReportableSegments2Member5002572025-06-30in-capmkt:ReportableSegments2Member5002572025-04-012025-06-30in-capmkt:ReportableSegments8Member5002572025-06-30in-capmkt:ReportableSegments8Member5002572025-04-012025-06-30in-capmkt:ReportableSegments9Member5002572025-06-30in-capmkt:ReportableSegments9Member5002572025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15002572025-04-012025-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares500257LUPINNOTLISTEDINE326A01037Lupin LimitedMain BoardEquity2025-04-012026-03-312025-08-052025-07-21INRMillionsQuarterlyFirst quarterMulti segment2025-08-0517:00:002025-08-0519:40:00Not applicable2025-04-012025-06-30UnauditedConsolidated6268340000079040000063473800000112663000007139500000-6865000001083000000091760000029898000001686170000049318400000141554000000141554000004908900000-2968100000194080000001221460000000001221460000016022000001381680000012190300000243000001377300000043800000913500000226.726.620026.726.621. The above Consolidated Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 05, 2025. The Statutory Auditors of the Company have carried out limited review of the above Consolidated Financial Results pursuant to Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. <BR> <BR> 2. The Consolidated Financial Results include the financial results of the subsidiaries, Lupin Pharmaceuticals, Inc. U.S.A., Lupin Australia Pty Limited Australia, Nanomi B.V. Netherlands, Pharma Dynamics Proprietary Limited South Africa, Hormosan Pharma GmbH Germany, Multicare Pharmaceuticals Philippines Inc. Philippines, Lupin Atlantis Holdings SA Switzerland, Lupin Healthcare UK Limited U.K., Lupin Pharma Canada Limited Canada, Generic Health Pty Limited Australia, Lupin Mexico S.A. de C.V. Mexico, Lupin Philippines Inc. Philippines, Lupin Diagnostics Limited, India, Generic Health SDN. BHD., Malaysia, Lupin Inc., U.S.A., Laboratorios Grin S.A. de C.V. Mexico, Medquimica Industria Farmaceutica LTDA Brazil, Novel Laboratories, Inc. U.S.A., Lupin Research Inc. U.S.A., Lupin Management Inc. U.S.A, Lupin Europe GmbH Germany, Lupin Biologics Limited India, Lupin Oncology Inc. U.S.A, Lupin Digital Health Limited India, Avenue Coral Springs LLC U.S.A., Southern Cross Pharma Pty Ltd Australia, Lupin Life Sciences Limited India formerly known as Lupin Atharv Ability Limited India, Lupin Manufacturing Solutions Limited India, Medisol S.A.S. France, Lupin Lanka Private Ltd. Sri Lanka w.e.f. August 05, 2024, Lupin NZ Ltd. New Zealand w.e.f. August 08, 2024, Lupinlife Consumer Healthcare Limited India w.e.f. March 08, 2025, Renascience Pharma Limited U.K. w.e.f. April 02, 2025 and a joint venture, YL Biologics Limited Japan. <BR> <BR> 3. The Consolidated Financial Statements are prepared in accordance with Ind AS 110 Consolidated Financial Statements and Ind AS 28 Investments in Associates and Joint Ventures. <BR> <BR> 4. During the quarter ended June 30, 2025, the Company through its wholly owned step down subsidiary, Lupin Healthcare UK Limited, acquired 100% equity share capital of Renascience Pharma Limited, U.K. for a consideration of Rs. 1,361.6 million GBP 12.3 million. Currently, the purchase consideration has been allocated on a provisional basis based on managements estimates. <BR> <BR> 5. During the quarter ended June 30, 2025, 151,078 equity shares of Rs. 2 each, fully paid up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans ESOPs, resulting in an increase in the paid up share capital by Rs. 0.3 million and securities premium account by Rs. 146.1 million. <BR> <BR> <BR> 6. During the year ended March 31, 2025, the Group has made a provision of Rs. 1,441.2 million USD 17.0 million respectively towards ongoing disputes. <BR> <BR> 7. During the quarter ended June 30, 2024 and year ended March 31, 2025, Lupin Limited and its subsidiary, agreed to settle the dispute for an amount of USD 9.0 million Rs. 750.5 million in connection with the drug Glumetza without admitting any liability for any wrongdoing, with a view to avoid the costs and uncertainties of continued litigation. <BR> <BR> 8. During the quarter and year ended March 31, 2025, the Group has recognised an impairment charge of Rs. 1,135.3 milion and Rs. 1,209.0 milion respectively related certain property, plant and equipment, capital work in progress, intangible assets, intangible assets under development and goodwill. <BR> <BR> 9. The figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter ended December 31, 2024. The year to date figures up to the third quarter ended December 31, 2024 were only subject to Limited Review and not audited. Review and not audited. <BR> Other expenses17720400000Net (gain) / loss on foreign currency transactions-858700000Pharmaceuticals62364100000Others322800000Less: Inter segment Assets0Less: Inter segment Liabilities062686900000350000062683400000Pharmaceuticals14578400000Others-423000000Less: Inter segment Assets0Less: Inter segment Liabilities0141554000000014155400000Pharmaceuticals318909900000Others2229400000Less: Inter segment Assets-3522700000Less: Inter segment Liabilities03176166000000317616600000Pharmaceuticals129854800000Others3070000000Less: Inter segment Assets0Less: Inter segment Liabilities-21158000001308090000000130809000000Items that will not be reclassified subsequently to profit or loss-103500000-103500000-36200000Items that will be reclassified subsequently to profit or loss16949000001694900000254000001602200000